Insmed Inc is primarily active in the biopharmaceutical industry, specializing in the development and commercialization of novel therapies for patients with serious and rare diseases. With a focus on respiratory and infectious diseases, Insmed Inc aims to address unmet medical needs and improve the lives of patients. As a leading player in the biopharmaceutical sector, Insmed Inc is committed to advancing innovative solutions and creating value for shareholders, healthcare providers, and patients alike.

The main competitors of Insmed Inc in the market include other pharmaceutical companies such as Gilead Sciences, Novartis, AstraZeneca, and GlaxoSmithKline. These companies operate in the same industry and compete with Insmed Inc in the development and commercialization of innovative therapies. Their products and services may overlap with Insmed Inc's, creating competition for market share and the pursuit of specific indications and patient populations. By staying informed about the activities and progress of these competitors, investors can gain insights into the dynamic landscape of the pharmaceutical industry and make more informed investment decisions.

Insmed Inc is a biopharmaceutical company headquartered in Bridgewater, New Jersey. Founded in 1988, Insmed focuses on the development and commercialization of therapies for serious and rare diseases. The company primarily concentrates on the discovery and development of novel drugs to address unmet medical needs, particularly in the field of severe lung diseases. Over the years, Insmed has made significant advancements in scientific research and clinical trials, resulting in the approval of its flagship product, ARIKAYCE®, for the treatment of Mycobacterium avium complex lung disease. With a strong commitment to innovation and improving patients' lives, Insmed Inc has established itself as a leading player in the biopharmaceutical industry.

Insmed Inc, a leading biopharmaceutical company, has accomplished several significant milestones. In recent years, Insmed Inc received FDA approval for its breakthrough drug, ARIKAYCE®, a treatment for Mycobacterium avium complex (MAC) lung disease. This achievement marked a major breakthrough in respiratory medicine. Additionally, Insmed Inc has successfully advanced the development of novel therapies, such as brensocatib for bronchiectasis, establishing its position as a pioneer in the field. Through its dedication to scientific innovation and commitment to improving patient outcomes, Insmed Inc continues to achieve remarkable milestones, reinforce its reputation, and shape the future of the healthcare industry.

Insmed Inc is primarily present in the United States.

Insmed Inc is a leading biopharmaceutical company committed to transforming the lives of patients with serious and rare diseases. With a strong corporate philosophy centered around innovation, collaboration, and patient-centricity, Insmed strives to deliver breakthrough therapies that address unmet medical needs. The company values integrity, scientific excellence, and empathy, aiming to make a positive impact on the lives of patients worldwide. Insmed Inc focuses on developing advanced therapies using its proprietary platform technologies and leveraging its extensive industry knowledge and expertise. By constantly pushing boundaries and advocating for patients, Insmed embodies a commitment to improving healthcare outcomes and enhancing the quality of life for those in need.

Analysts currently set an average price target of 219,19 USD for the Insmed stock (median: 217,77 USD), implying +118,4 % versus the latest price. The consensus is based on 27 analyst ratings.

Insmed Analyytikkojen kursstavoitteet 2026

27 analysts currently rate the Insmed stock: 25 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Insmed to generate revenue of 1,70 Mrd. USD and earnings per share of −2,62 USD.

Insmed Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Insmed share trades at 86,89 EUR (100,37 USD).

The Insmed share (INSM) is listed on 5 stock exchanges, including: NASDAQ (INSM), Frankfurt (IM8N.F), London (0JAV.L), London (0JAV.L), SIX (Zürich) (IM8N.SW).

Insmed Inc is a biopharmaceutical company focused on developing and marketing therapies for patients with rare lung diseases and serious infections. The company operates in three core business areas: product development, marketing of approved therapies, and diagnostic services. Insmed Inc invests heavily in research and development, particularly in the potential of inhalation drugs for targeted treatment of lung diseases such as cystic fibrosis and non-tuberculous mycobacterial infections. They also market approved therapies, like Arikayce, and offer diagnostic services with an innovative lung function diagnostic system. The goal of their business model is to create value for patients, doctors, and investors, positioning themselves as a leading company in this field. However, regulatory conditions may pose risks and delay the market entry of new therapies. Overall, Insmed Inc is an exciting company of great interest to investors and the medical community, contributing to saving lives and improving the quality of life for patients worldwide.

odotettu liikevaihto Insmed on 1,70 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Insmed on −558,82 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Insmed:n hinta-voitto-suhde (P/E) on tällä hetkellä −38,37. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Insmed-osakkeen arvostusta.

Insmed:n hinta-myynti-suhde (P/S) on tällä hetkellä 12,62. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Insmed-osakkeen arvostuskennuslukuna.

Insmed:n Eulpool-laatuscore on 4/10.

Insmed:n ISIN on US4576693075. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Insmed:n WKN on A1JJA3. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Insmed:n ticker on INSM. Tämä pörssinoteeraus käytetään Insmed-osakkeiden kauppaan pörssissä.

Insmed maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Insmed kuuluu sektoriin 'Terveydenhuolto'.

Insmed:n osingot jaetaan valuutassa USD.